In part 3 of this Exclusive Interview, John Buse talks with Diabetes in Control Publisher Steve Freed about the heart complication and amputation risks on the greater population.
Read More »Association Between Use of Sodium Glucose Cotransporter 2 Inhibitors and Serious Adverse Effects
Study findings warrant cautious consideration and discussions about risk vs benefit when considering therapy.
Read More »Novel Use of SGLT-2 Inhibitors for Treatment of Early-Stage Lung Adenocarcinoma
Study assessed association of cancer and sodium glucose transporter 2 expression as well as potential benefit of SGLT-2 treatment.
Read More »Comparison of Cognitive Benefit Between SGLT-2 Inhibitors and Incretins
Which antihyperglycemic agent will provide the greater cognitive benefit in patients who are elderly and have diabetes?
Read More »Canagliflozin in Patients with Diabetes and Kidney Disease
Can canagliflozin affect the progression of kidney disease in patients with type 2 diabetes?
Read More »Javed Butler Part 1, Evolving Landscape Of Diabetes Heart Failure
In part 1 of this Exclusive Interview, Javed Butler talks with Diabetes in Control Publisher Steve Freed about the use of SGLT to lower risk of heart disease.
Read More »Javed Butler Part 4, How Do SGLT2 Inhibitors Impact Heart Failure
In part 4, the conclusion of this Exclusive Interview, Javed Butler talks with Diabetes in Control Publisher Steve Freed about the use of SGLT2 to help prevent heart failure but not as a current treatment method.
Read More »SGLT-2i Use in Type 1 Diabetes May Help Maintain Glycemic Levels
Empagliflozin shows improvements in A1C while also having major adverse effects, but there could be a balance.
Read More »Sotagliflozin As Adjunct Therapy for People with Type 1 to Increase Time in Target Range
Researchers seek development of drug therapies and technologies to assist in achieving additional time in glucose target range and less hypoglycemia.
Read More »Sotagliflozin Shows Promise As Adjunct To Insulin Therapy
New SGLT1/SGLT2 inhibitor lowers HbA1c and has less hypoglycemia episodes among people who have type 1 diabetes.
Read More »